Global Lung Cancer Liquid Biopsy Market 2020-2024

Global Lung Cancer Liquid Biopsy Market 2020-2024

The publisher has been monitoring the lung cancer liquid biopsy market and it is poised to grow by $ 292.89 mn during 2020-2024, progressing at a CAGR of 16% during the forecast period. The reports on the lung cancer liquid biopsy market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven rising incidence of lung cancer, increasing participation in conferences to endorse the products and technologically advanced products. In addition, the rising incidence of lung cancer is anticipated to boost the growth of the market as well.

The lung cancer liquid biopsy market analysis includes product segment and geographical landscapes.

The lung cancer liquid biopsy market is segmented as below:

By Product

• CTCs and ctDNA
• Exosomes and RNA

By Geographical Landscapes

• North America
• Europe
• Asia
• ROW

This study identifies the growing partnership agreements as one of the prime reasons driving the lung cancer liquid biopsy market growth during the next few years. Also, vendors' focus on clinical trials and application of liquid biopsy for personalized treatment will lead to sizable demand in the market.

The lung cancer liquid biopsy market report covers the following areas:

• Lung cancer liquid biopsy market sizing
• Lung cancer liquid biopsy market forecast
• Lung cancer liquid biopsy market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lung cancer liquid biopsy market vendors that include Biocartis Group NV, Biocept Inc., Bio-Rad Laboratories Inc., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Sysmex Corp., Thermo Fisher Scientific Inc., and Trovagene Inc. Also, the lung cancer liquid biopsy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.